Pathophysiology of heparan sulphate: many diseases, few drugs - sprookjes - yvandenbroek - TriplyDB

Pathophysiology of heparan sulphate: many diseases, few drugs

Pathophysiology of heparan sulphate: many diseases, few drugs

http://www.wikidata.org/entity/Q26823840

about

Marine Origin Polysaccharides in Drug Delivery Systems.Diverse Roles of Heparan Sulfate and Heparin in Wound Repair Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications Extracellular matrix components in the pathogenesis of type 1 diabetes.Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.Identification of chondroitin sulfate linkage region glycopeptides reveals prohormones as a novel class of proteoglycans Diversity of heparan sulfate and HSV entry: basic understanding and treatment strategies.Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential o-6 protections: programming for regiodefined 6-o-modifications.Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix The Interaction of Heparin Tetrasaccharides with Chemokine CCL5 Is Modulated by Sulfation Pattern and pH Heparan Sulfate Modulates Neutrophil and Endothelial Function in Antibacterial Innate Immunity Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo.Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology.Using isothermal titration calorimetry to determine thermodynamic parameters of protein-glycosaminoglycan interactions Human papillomavirus capsids preferentially bind and infect tumor cells.Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis Flexible Linker Modulates Glycosaminoglycan Affinity of Decorin Binding Protein A.Enhanced effect of fibroblast growth factor-2-containing dalteparin/protamine nanoparticles on hair growth.Glycan Sulfation Modulates Dendritic Cell Biology and Tumor Growth.Tissue-specificity of heparan sulfate biosynthetic machinery in cancer.Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity Single-Molecule Fluorescence Detection of a Synthetic Heparan Sulfate Disaccharide.Alteration of colonic epithelial cell differentiation in mice deficient for glucosaminyl N-deacetylase/N-sulfotransferase 4.Varicella-zoster virus and herpes simplex virus 1 can infect and replicate in the same neurons whether co- or superinfected.Heparin/heparan sulphate interactions with complement--a possible target for reduction of renal function loss?Heparan sulfate in angiogenesis: a target for therapy.Heparan Sulfate Microarray Reveals That Heparan Sulfate-Protein Binding Exhibits Different Ligand Requirements.Integrated Approach to Identify Heparan Sulfate Ligand Requirements of Robo1.Identification of RNA Oligonucleotides Binding to Several Proteins from Potential G-Quadruplex Forming Regions in Transcribed Pre-mRNA.PRRSV receptors and their roles in virus infection.Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.Syntenin and syndecan in the biogenesis of exosomes.Mechanistic and therapeutic overview of glycosaminoglycans: the unsung heroes of biomolecular signaling.Different Use of Cell Surface Glycosaminoglycans As Adherence Receptors to Corneal Cells by Gram Positive and Gram Negative Pathogens Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.Transcriptional Activity of Heparan Sulfate Biosynthetic Machinery is Specifically Impaired in Benign Prostate Hyperplasia and Prostate Cancer.SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.Targeting heparin and heparan sulfate protein interactions.

P2860

Q26767227-395C7402-7C12-4E5A-80DC-475937B1BE55 Q26799832-FA59EEB4-FB8E-4AFA-AAF0-6764D6743C6E Q27347532-FCBB8120-187A-428E-B870-8ADC90555553 Q33851544-1F925876-09EA-4AAE-92A7-95237DC4A14C Q34546894-8D03525A-2B78-48D4-813D-B816960A8CF0 Q34549794-662D0D55-376E-47B1-9D99-88AECA3E801E Q34884277-B36C4380-FDB8-4E62-A2CC-5D5EB14412A7 Q35558287-0C2EF42D-9E44-4124-9AC0-BF3043C1DA1D Q35574973-DE5E3A9A-6841-4BCD-8131-0CF73584E40A Q35723975-7221C69A-CFC4-4D04-89E7-8E71392321EB Q35860612-0C149670-3CA0-4399-9B45-271E9F95ADF4 Q35947370-4DB62FAF-2F8E-4C16-83EF-197787A1C2E6 Q36094711-F251E2B7-311B-405C-BE8B-D6FA721C442F Q36169514-CFE0952D-8577-4453-A24F-28D1661A07FB Q36402415-D0A72131-FC3D-4708-95DF-0BBD0F40BF01 Q36470809-15EE8CD6-27BA-4116-AFBC-83FA103358C2 Q36498218-77F1D19A-D283-4EE4-8F94-C99500DC0A38 Q36917309-8DF8F857-AE55-4FFD-83F9-4BF577283C83 Q36926165-830F3433-E710-443E-9A39-CBFDC06A1B28 Q36952955-B5DF621B-429D-44B2-9AB1-8CB6739A5492 Q37114695-0769EDCB-8960-4CFF-8F82-42ACD4BDB525 Q37400143-52A43658-68F8-49E2-9A2C-7C6ACF141402 Q37417671-799217C3-0FA8-45BC-B149-669DF1D689BD Q37709048-998DA55D-516D-458B-BF15-ABF1443343F3 Q37713956-7F362429-A88F-4360-80C4-82DCC040B817 Q38123661-7D354FD4-2C97-4738-ABAB-578E6EFD8038 Q38154506-44008755-C1A6-4C11-ACCA-D0D0874CA774 Q38287875-2BCC21DC-DB49-4154-B16C-C652B25CB2C5 Q38290964-5A0AA317-50CA-40D8-AEBC-53145628D389 Q38295068-3D046A39-5D9C-4AE6-843C-762130659299 Q38350104-DE9EBC16-0EA5-4FE7-869D-DABEE654374B Q38418286-D7290F2B-4872-4CDB-B7EE-021C267B26C3 Q38511561-C916265C-9766-4BE8-8463-1BF20921D07D Q38658691-FD2A20C6-5903-4FBE-9A4A-5ACDE8269C41 Q38726317-7DC209C6-36B0-470E-9D8C-D6FEDC2FA00E Q38801721-33758C84-B163-4FCC-BC92-73568C9A07FB Q38883962-E8420EB9-F267-45F1-B47E-CF26C6E5FB7E Q38885517-C7AE2AA2-5878-47A9-BCF5-A51A2A2A9360 Q39060517-C85AD474-1396-41F3-BEA1-0AB881A3BBD8 Q39399937-C5C63A2D-3611-413F-9B0A-6A32C23DA479

P2860

Pathophysiology of heparan sulphate: many diseases, few drugs

http://www.wikidata.org/entity/Q26823840

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pathophysiology of heparan sulphate: many diseases, few drugs

@ast

Pathophysiology of heparan sulphate: many diseases, few drugs

@en

Pathophysiology of heparan sulphate: many diseases, few drugs

@nl

type

label

Pathophysiology of heparan sulphate: many diseases, few drugs

@ast

Pathophysiology of heparan sulphate: many diseases, few drugs

@en

Pathophysiology of heparan sulphate: many diseases, few drugs

@nl

prefLabel

Pathophysiology of heparan sulphate: many diseases, few drugs

@ast

Pathophysiology of heparan sulphate: many diseases, few drugs

@en

Pathophysiology of heparan sulphate: many diseases, few drugs

@nl

P1433

Q26823840-9178EA31-900A-45DB-B1E6-CCBCC66E4F14

P1476

Q26823840-0A6D6AFA-08D9-427F-9F55-B9FC0683EA27

P2093

Q26823840-06E4B9CB-5659-4E6D-85C3-76E4123AFBE0

Q26823840-3924C64E-57EA-45A2-842E-EAE1E714958B

P2860

Q26823840-0119157C-10A8-48A1-9234-9A53E25D8BFA

Q26823840-02001F34-059C-4F08-975A-E03DD74962A6

Q26823840-03DEF5F8-98A3-4781-9D46-3E0FF75F6978

Q26823840-05F88F0E-F321-4E84-B1AD-793D8CB23DB7

Q26823840-075D0794-2D8F-413A-9E61-D43B318B33B0

Q26823840-0AC7B8AF-2CA5-4458-8067-AAF5DBBBA879

Q26823840-0B4C29BE-E099-4EBC-A430-250BD314A115

Q26823840-0BA318C5-5BFC-47D6-996D-E51BC9D5F6CF

Q26823840-0E828F42-7C72-4F7E-959E-9AD94C1D2480

Q26823840-0F24AEFA-B9DE-4D4D-A8A5-4B690AC23F90

P304

Q26823840-E4C671DD-446F-4C22-A281-4BA2442787BA

P31

Q26823840-069041DB-5ED4-42CC-B811-022A81F52228

P3181

Q26823840-ED237BC6-1EE9-4997-B257-2EDDAC7757A2

P356

Q26823840-2818C723-C457-4BE7-BEF1-2CFF100E6F42

P407

Q26823840-3B83C6F3-40D3-40F7-8092-731A174D9FEB

P433

Q26823840-CC22DE25-9379-47BA-94D8-86E1C5D401D6

P478

Q26823840-A9B4CEF2-85BF-4DE3-9A5B-0F2670E7D0EF

P577

Q26823840-F0C3E258-0E40-4A01-8716-3F7FA67D08D5

P5875

Q26823840-DA189073-661C-42AA-9013-9346E2C46026

P698

Q26823840-0A2E237E-A40A-4E7A-B431-A380DFFE9BE6

P921

Q26823840-4AC44B3E-A1A6-4A52-8E74-B71C5D743A66

P3181

P356

P1433

Journal of Internal Medicine

P1476

Pathophysiology of heparan sulphate: many diseases, few drugs

@en

P2093

L. Kjellén

http://www.w3.org/2001/XMLSchema#string

U. Lindahl

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities

Heparin-binding protein targeted to mitochondrial compartments protects endothelial cells from apoptosis

The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate

Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome)

Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin

Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2)

Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism

The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate

Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides

Enzyme interactions in heparan sulfate biosynthesis: uronosyl 5-epimerase and 2-O-sulfotransferase interact in vivo

P304

555-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1042845

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/JOIM.12061

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

273

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235713822

http://www.w3.org/2001/XMLSchema#string

P698

23432337

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology